Search research articles
Contact Us
Filters
Showing results (101-110 of 210) with videos related to
Page
of 21
Sort By:
The Lancet. Oncology
|
April 2, 2026
Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
Melissa L Johnson, Manish R Patel, Gerald S Falchook, et al.
Clinical Lung Cancer
|
September 23, 2023
Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review
Jürgen Wolf, Pierre-Jean Souquet, Koichi Goto, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 26, 2025
Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLC
Malini M Gandhi, Arielle Elkrief, Catherine Gutierrez Moore, et al.
Cell Reports. Medicine
|
October 15, 2025
Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironment
James R Lindsay, Jennifer Altreuter, Joao V Alessi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 15, 2021
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407
Steven F Powell, Delvys Rodríguez-Abreu, Corey J Langer, et al.
Journal for Immunotherapy of Cancer
|
November 26, 2021
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
Joao V Alessi, Biagio Ricciuti, Stephanie L Alden, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 5, 2023
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial
Edward B Garon, Alexander I Spira, Sarah B Goldberg, et al.
Cancer Cell
|
September 29, 2023
Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden
Mingrui Zhu, Jiwoong Kim, Qing Deng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 10, 2018
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer
Lorena Ostios-Garcia, Jennifer Faig, Giulia C Leonardi, et al.
JAMA Oncology
|
June 4, 2026
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis
Alessandro Di Federico, Samuele Compagno, Francesco Mantuano, et al.
Page
of 21
Search research articles
Search
Showing results (101-110 of 210) with videos related to
Sort By:
Page
of 21
The Lancet. Oncology
|
April 2, 2026
Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
Melissa L Johnson, Manish R Patel, Gerald S Falchook, et al.
Clinical Lung Cancer
|
September 23, 2023
Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review
Jürgen Wolf, Pierre-Jean Souquet, Koichi Goto, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 26, 2025
Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLC
Malini M Gandhi, Arielle Elkrief, Catherine Gutierrez Moore, et al.
Cell Reports. Medicine
|
October 15, 2025
Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironment
James R Lindsay, Jennifer Altreuter, Joao V Alessi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 15, 2021
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407
Steven F Powell, Delvys Rodríguez-Abreu, Corey J Langer, et al.
Journal for Immunotherapy of Cancer
|
November 26, 2021
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
Joao V Alessi, Biagio Ricciuti, Stephanie L Alden, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 5, 2023
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial
Edward B Garon, Alexander I Spira, Sarah B Goldberg, et al.
Cancer Cell
|
September 29, 2023
Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden
Mingrui Zhu, Jiwoong Kim, Qing Deng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 10, 2018
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer
Lorena Ostios-Garcia, Jennifer Faig, Giulia C Leonardi, et al.
JAMA Oncology
|
June 4, 2026
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis
Alessandro Di Federico, Samuele Compagno, Francesco Mantuano, et al.
Page
of 21